For an older adult (≥65 years) with chronic constipation, should I use Movicol (polyethylene glycol 3350) or lactulose as first‑line therapy?

Use Movicol (Polyethylene Glycol 3350) as First-Line Therapy in Geriatric Patients with Chronic Constipation

Polyethylene glycol (PEG) 3350 should be your first-line pharmacological choice for older adults with chronic constipation, as it demonstrates superior efficacy, better tolerability, and fewer side effects compared to lactulose. 1

Guideline-Based Recommendation Hierarchy

The 2023 AGA-ACG joint clinical practice guideline provides clear direction:

• PEG receives a STRONG recommendation for chronic idiopathic constipation in adults 1
• Lactulose receives only a CONDITIONAL recommendation and is positioned as a second-line agent "for adults who fail or are intolerant to OTC therapies" 1

This hierarchical positioning is critical—the guideline explicitly places lactulose after PEG in the treatment algorithm.

Why PEG 3350 is Superior in Geriatric Patients

Efficacy Advantages

PEG produces significantly more bowel movements per week:

• Meta-analysis shows PEG yields an additional 1 stool per week compared to lactulose (p=0.0017) 2
• In elderly-specific trials, PEG achieved significantly higher stool frequency (p<0.05) and improved stool consistency (p<0.05) at every monthly evaluation over 6 months 3
• A head-to-head comparison demonstrated 1.3 vs 0.9 bowel movements per day (PEG vs lactulose, p=0.005) 4

Tolerability Profile—Critical in Geriatrics

Lactulose's major limitation is dose-dependent bloating and flatulence 1, which the guidelines specifically note "may limit its use in clinical practice." This is particularly problematic in elderly patients who:

• May already have baseline bloating or functional dyspepsia
• Are more sensitive to gastrointestinal side effects
• May discontinue therapy due to discomfort

In contrast, PEG demonstrated significantly fewer side effects in elderly patients (15 vs 23 patients with adverse events, p=0.02), with lactulose causing predominantly bloating and abdominal pain 5. After 6 months of PEG treatment in elderly patients, no clinically relevant changes in biochemical or nutritional parameters were detected 3.

Practical Prescribing for Geriatric Patients

Starting Regimen

• Initial dose: 17 g (one packet) daily dissolved in 125-250 mL of water 1
• Can be taken at any time of day
• No maximum dose, but typically 17-34 g/day is sufficient

Dose Titration

• Adjust based on symptom response and side effects 1
• Goal: 2-3 soft stools daily
• If inadequate response after 3-5 days, increase by 8.5-17 g increments

Duration

• Response is durable over 6 months 1
• Long-term use (52 weeks) shows sustained efficacy with continued good tolerability 6

When to Consider Lactulose (Second-Line)

Reserve lactulose for patients who:

• Fail PEG therapy after adequate trial (2-4 weeks at optimized doses) 1
• Are intolerant to PEG (rare—primarily loose stools or nausea)
• Have severe renal insufficiency where you're avoiding all osmotic agents (though PEG is generally safe)

If using lactulose:

• Start 15 g (15 mL) daily 1, 7
• Titrate to 15-30 mL twice daily as needed
• Warn patients explicitly about bloating/gas to improve adherence

Critical Geriatric-Specific Considerations

Elderly patients on immunosuppression or with multiple comorbidities are at higher risk for complications 8, but this relates to their underlying conditions, not laxative choice. However:

• Ensure adequate hydration with any osmotic laxative
• Monitor for electrolyte disturbances in frail elderly (though rare with PEG)
• PEG showed no malabsorption concerns (D-xylose testing) over 6 months in elderly 3
• No impact on nutritional status (MNA scores remained stable) 3

Common Pitfalls to Avoid

1. Don't start with lactulose out of habit—the evidence clearly favors PEG as first-line
2. Don't underdose PEG—17 g daily is the starting point; many patients need more
3. Don't abandon PEG prematurely—give it 3-5 days minimum before declaring failure
4. Don't forget fiber supplementation—can be used before or with PEG for mild constipation 1

The Evidence Quality Gap

While PEG has strong evidence (moderate certainty) 1, lactulose evidence is notably weaker:

• Very low certainty of evidence for lactulose 1
• Only 2 RCTs in elderly populations for lactulose 1
• Concerns about risk of bias and imprecision in lactulose trials 1

The single most compelling piece of evidence is the 2023 AGA-ACG guideline's strong vs. conditional recommendation distinction, combined with the explicit positioning of lactulose as second-line therapy. 1